Pfizer Licenses Halozyme's Enhanze Technology

Pfizer (NYSE: PFE  ) has licensed Halozyme Therapeutics' (NASDAQ: HALO  ) Enhanze technology, which the pharmaceutical giant plans to combine with its biologics. The technology allows drugs that would otherwise have to be administered intravenously or require multiple injections to be delivered subcutaneously -- just below the surface of the skin.

Two therapeutic targets in primary care and specialty care indications have already been identified, for which Pfizer will pay Halozyme $8 million. The license also allows Pfizer to select four additional targets upon payment of additional undisclosed fees.

Halozyme is eligible to receive additional payments of up to $507 million if Pfizer achieves specific development, regulatory, and sales-based milestones.

The biotech has licensed the Enhanze technology to four other companies: Baxter (NYSE: BAX  ) , Roche (NASDAQOTH: RHHBY  ) , Viropharma (NASDAQ: VPHM  ) , and Interexon.

link


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2166551, ~/Articles/ArticleHandler.aspx, 7/28/2014 4:34:58 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASD 4,449.56 -22.54 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/25/2014 3:59 PM
HALO $9.10 Down -0.10 -1.09%
Halozyme Therapeut… CAPS Rating: ***
PFE $30.19 Down -0.15 -0.49%
Pfizer CAPS Rating: ****
BAX $76.65 Down -0.35 -0.45%
Baxter Internation… CAPS Rating: *****
VPHM $0.00 Down +0.00 +0.00%
ViroPharma, Inc. CAPS Rating: ***

Advertisement